Medline: Company Apparently Did Not Disclose Systemic Problems Identified in Multiple FDA Inspections in Year Prior to IPO

Last December, Medline (MDLN), one of the largest suppliers of medical and surgical products in the country, went public in the biggest IPO of the year, raising over $6 billion. In the 12 months prior to the IPO, Medline received four Form 483 inspection reports…

Published on Apr 16, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.